RT @ericdeinmd: Dr. Furie: #RNL2023 Anifrolumab - anti type 1 IFN receptor- blocks all 5 IFN, 90% IFN gene signature dec
Tweet Content
Dr. Furie: #RNL2023
Anifrolumab - anti type 1 IFN receptor- blocks all 5 IFN, 90% IFN gene signature decrease
Improved from prior older failed medication sifalimumab which only blocked IFNalpha- only 25% interferon gene signature
@RheumNow https://t.co/30oFRwwuTG
Show on Archive Page
On
Display in Search Results
On
PDQ
Off